Ocugen Doses First Patient in OCU410 Phase 3; DMC Flags Futility Risk in OCU410ST Interim Analysis
OCGN sits 32% above its 52-week low of $1.01.
Summary
Ocugen dosed the first patient in its OCU410 Phase 3 trial for geographic atrophy, but the DMC for its OCU410ST Stargardt trial flagged a negative treatment effect in an interim analysis, recommending continuation only to obtain full 8-month data.
Key Events · Product Development and Regulatory · OCGN
-
First Patient Dosed in OCU410 Phase 3
On September 1, 2026, Ocugen dosed the first patient in the global Phase 3 registrational trial of OCU410 for geographic atrophy secondary to dry AMD, following FDA alignment on all critical Phase 3 design elements.
-
DMC Flags Futility Risk in OCU410ST
The independent DMC for the Phase 2/3 OCU410ST trial in Stargardt disease noted one could consider futility based on the negative direction of treatment effect in the interim sample of 26 subjects, but recommended continuing to obtain 8-month follow-up on the entire study population.
-
Baseline Imbalance Cited as Mitigating Factor
The DMC attributed the negative interim signal to a baseline lesion size imbalance between treatment and control arms in the small interim analysis population, which does not exist in the full dataset at 8 months.
-
Going Concern and Shareholder Vote Loom
This update arrives ahead of the September 21, 2026 special meeting to authorize 250 million new shares needed to settle convertible notes, while the company operates under a going concern warning disclosed in its Q2 10-Q.
Analysis · OCGN · Life Sciences
Ocugen has dosed the first patient in its global Phase 3 registrational trial of OCU410 for geographic atrophy, a milestone that moves its lead gene therapy candidate into the final stage of development. However, the same filing reveals that the independent Data Monitoring Committee for the OCU410ST Phase 2/3 trial in Stargardt disease noted a negative direction of treatment effect in a small interim sample — a signal that the trial could fail on futility grounds once the full 8-month dataset is analyzed. The DMC recommended continuing the study to obtain complete follow-up data, citing a baseline lesion size imbalance in the interim population that does not exist in the full dataset. This mixed update comes as Ocugen faces a going concern warning and a critical September 21 shareholder vote to authorize shares needed to settle convertible notes.
How filings like this one have moved
In the 30 days to Sep 10, 2026, 30.2% of the 2009 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.11%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, OCGN was trading at $1.33 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $451M. The 52-week trading range was $1.01 to $2.73. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.